Holen Sie sich die Stockscreener-App
8.28
3.45%
0.30
Handel nachbörslich:
8.30
0.02
+0.24%
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
CorMedix eyes REZZAYO expansion as DefenCath reimbursement shift looms - MSN
Cormedix outlines $325M-$345M 2026 net revenue outlook amid TDAPA transition - MSN
CRMD: Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets - TradingView
CRMD Q1 earnings beat on DefenCath momentum, guidance raised - MSN
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms - Yahoo Finance
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CorMedix stock jumps as DefenCath fuels Q1 beat, 2026 outlook raised - MSN
Cormedix Earnings Call Highlights Surging Growth, New Risks - TipRanks
CorMedix Q1 earnings call highlights - MSN
CorMedix banks on DefenCath sales in Q4 as Melinta adds upside - MSN
UBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMD - MarketBeat
Needham Maintains CorMedix (CRMD) Buy Recommendation - MSN
Discipline and Rules-Based Execution in CRMD Response - Stock Traders Daily
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD) - Seeking Alpha
HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD) - MarketBeat
Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)? - Yahoo Finance
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results - simplywall.st
A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance - Yahoo Finance
CorMedix Inc $CRMD Shares Bought by Vanguard Group Inc. - MarketBeat
RBC Capital Keeps Their Buy Rating on Cormedix (CRMD) - The Globe and Mail
CorMedix (CRMD) Q1 earnings and revenues beat estimates - MSN
CorMedix Inc.Common Stock (NQ: CRMD - The Chronicle-Journal
symbol__ Stock Quote Price and Forecast - CNN
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - The Globe and Mail
A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $13 to $15 - Moomoo
Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership - Stock Titan
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences - marketscreener.com
CorMedix Inc. (NASDAQ:CRMD) Q1 2026 Earnings Call Transcript - Insider Monkey
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Sahm
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised - Sahm
Cormedix Earnings Call Highlights Growth, Raises Outlook - TipRanks
CorMedix Inc. Stock 12‑Month Price Target Cut to $14.86, Implies 98% Upside - TradingView
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge - Stocktwits
CorMedix Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
CorMedix (NASDAQ:CRMD) Issues Earnings Results - MarketBeat
CorMedix (CRMD) Q1 2026 Earnings Transcript - AOL.com
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
CorMedix 1Q EPS 43c >CRMD - Moomoo
CORMEDIX INC. Reports Q1 2026 Financial Results and Business Update – SEC 8-K Filing Details - Minichart
Transcript : CorMedix Inc., Q1 2026 Earnings Call, May 14, 2026 - marketscreener.com
Earnings call transcript: CorMedix Q1 2026 revenue beats, stock surges - Investing.com UK
CorMedix Q1 Earnings Call Highlights - MarketBeat
CorMedix Shares Jump After Revenue Beat and Higher Full-Year Guidance - Yahoo Finance
CorMedix Releases Q1 2026 Financial Results - AlphaStreet
CRMD: Q1 revenue and profitability exceeded expectations, driving higher full-year guidance - TradingView
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):